natgillin/translations-raw huggingface dataset:
Non-melanoma skin cancer: Based on available data from epidemiological studies, cumulative dosedependent association between HCTZ and NMSC has been observed (see also sections 4.4 and 5.1). 
Nemelanomski kožni rak: Na podlagi obstoječih podatkov epidemioloških študij so ugotovili, da obstaja razmerje med kumulativnim odmerkom hidroklorotiazida in nemelanomskim kožnim rakom (glejte tudi poglavji 4.4 in 5.1).
However, aAddition of an alternative immunosuppressive agent to the corticosteroid regimen may should be considered in corticosteroid-refractory immune-related colitis if other causes are excluded (including Cytomegalovirus (CMV) infection/reactivation evaluated with viral PCR on biopsy, and other viral, bacterial and parasitic etiology) be considered. 
Pri imunsko pogojenem kolitisu, odpornem na zdravljenje s kortikosteroidi, je treba razmisliti Razmisliti je treba o dodatnem zdravljenju z drugim imunosupresivom, poleg zdravljenja s kortikosteroidi, če so izključeni drugi vzroki (vključno z okužbo/reaktivacijo okužbe s citomegalovirusom, ocenjenega z virusnim testom PCR po biopsiji, in drugo virusno, bakterijsko in parazitno etiologijo).
In clinical trials, immune-related colitis was associated with evidence of mucosal inflammation, with or without ulcerations, and lymphocytic and neutrophilic infiltration. 
V kliničnih preskušanjih je bil imunsko pogojeni kolitis povezan z znaki vnetja sluznice z razjedami ali brez ter z infiltracijo z limfociti in nevtrofilci.
Undesirable effects Tabulated list of adverse reactions Respiratory, thoracic and mediastinal disorders 
Preglednica z neželenimi učinki Bolezni dihal, prsnega koša in mediastinalnega prostora
Undesirable effects Tabulated list of adverse reactions Blood and lymphatic system disorders Frequency ‘uncommon': Thrombocytopenia 
Preglednica z neželenimi učinki Bolezni krvi in limfatičnega sistema Pogostnost „občasni“: trombocitopenija
Infections and infestations: cytomegalovirus infection - frequency uncommon 
Infekcijske in parazitske bolezni: okužba s citomegalovirusom - pogostnost „občasni“
Frequency ‘rare': Interstitial lung diseaseX 
Pogostnost „redki“: intersticijska bolezen pljučX
Special warnings and precautions Immune-related gastrointestinal reactions: 
Posebna opozorila in previdnostni ukrepi Imunsko pogojeni neželeni učinki v prebavilih:
Dimethyl fumarate (Tecfidera) - Immune thrombocytopenic purpura and thrombocytopenia (EPITT no 
Dimetilfumarat (Tecfidera) - imunska trombocitopenična purpura in trombocitopenija (EPITT št. 19192)
Protect your skin from sun exposure and UV rays while <taking> <using> X 4. 
Med <jemanjem> <uporabo> zdravila X zaščitite kožo pred izpostavljenostjo soncu in UV-žarkom.
Special warnings and precautions for use Infections 
Posebna opozorila in previdnostni ukrepi Okužbe
Frequency ‘rare': Eosinophilic pneumoniaY 
Pogostnost „redki“: eozinofilna pljučnicaY
The experience from clinical trials on the management of corticosteroid-refractory diarrhoea or colitis is limited. 
Izkušenj iz kliničnih preskušanj z zdravljenjem driske ali kolitisa, ki sta odporna na zdravljenje s kortikosteroidi, je malo.
Frequency ‘not known': Skin and lip cancer (Non-melanoma skin cancer) 
Možni neželeni učinki Pogostnost „neznana“: Kožni rak in rak ustnice (nemelanomski kožni rak)
Ipilimumab - Cytomegalovirus gastrointestinal infection (EPITT no 19207) 
Ipilimumab - okužba prebavil s citomegalovirusom (EPITT št. 19207)
Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients with positive family history of aneurysm disease, or in patients diagnosed with pre-existing aortic aneurysm and/or aortic dissection, or in presence of other risk factors or conditions predisposing for aortic aneurysm and dissection (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet's disease, hypertension, known atherosclerosis). 
Pri bolnikih s pozitivno družinsko anamnezo anevrizme ali pri bolnikih, ki so jim postavili diagnozo obstoječe aortne anevrizme in/ali aortne disekcije, ali v prisotnosti drugih dejavnikov tveganja ali stanj, ki so predispozicija za aortno anevrizmo in disekcijo (npr. Marfanov sindrom, vaskularna oblika Ehlers-Danlosovega sindroma, Takayasujev arteritis, velikocelični arteritis, Behçetova bolezen, hipertenzija, znana ateroskleroza), se smejo zato fluorokinoloni uporabljati le po natančni oceni razmerja med koristmi in tveganji ter razmisleku o drugih možnostih zdravljenja.
Post-marketing cases of cytomegalovirus (CMV) infection/reactivation have been reported in patients with corticosteroid-refractory immune-related colitis. 
Med obdobjem trženja zdravila so se pri bolnikih z imunsko pogojenim kolitisom, odpornim na zdravljenje s kortikosteroidi, pojavili primeri okužbe/reaktivacije okužbe s citomegalovirusom.
Cytomegalovirus (CMV) infections including cases of CMV reactivation have been reported in LEMTRADA-treated patients. 
Pri bolnikih, zdravljenih z zdravilom LEMTRADA, so poročali o okužbah s citomegalovirusom (CMV), vključno z reaktivacijo virusa CMV.
Frequency ‘not known': Non-melanoma skin cancer (Basal cell carcinoma and Squamous cell carcinoma) 
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi) Pogostnost „neznana“: Nemelanomski kožni rak (bazalnocelični karcinom in ploščatocelični karcinom)
Possible side effects Uncommon side effects These may affect up to 1 in 100 people: - reduction in blood platelets 
Pojavijo se lahko pri največ 1 od 100 bolnikov: - zmanjšanje števila trombocitov
Stool infections work-up should be performed upon presentation of diarrhoea or colitis to exclude infectious or other alternate etiologies. 
Ob pojavu driske ali kolitisa je treba izvesti analizo blata glede okužb, da se izključijo okužba ali drugi vzroki.
Alemtuzumab - Cytomegalovirus infection (EPITT no 
Alemtuzumab - okužba s citomegalovirusom (EPITT št. 19193)
Tell your doctor right away if you have symptoms of infection such as fever or swollen glands. 
Če imate simptome okužbe, na primer povišano telesno temperaturo ali otekle bezgavke, o tem nemudoma obvestite zdravnika.
ANNEX II[Not applicable for MRP/DCP] 
DODATEK PRILOGA II[Not applicable for MRP/DCP]
6.2 Major Iincompatibilities 
6.2 Glavne iInkompatibilnosti
<6 months.><…><1 year.><18 months.><2 years.><30 months.><3 years.><use immediately.> 
<6 mesecev> <...> <1 leto> <18 mesecev> <2 leti> <30 mesecev> <3 leta.> <uporabite takoj.>
Therefore, it is advisable not to treat animals on the same pasture every season.> 
Zato zdravljenje živali na istem pašniku vsako sezono ni priporočljivo.>
<{Invented name} should not enter water courses as this may be dangerous for fish and other aquatic organisms.> 
<{Izmišljeno ime} ne sme priti v vodotoke, ker je lahko nevaren za ribe in druge vodne organizme.>
<Official control authority batch release is required for this product.> [only for those immunological veterinary medicinal products which are listed for Official Control Authority Batch Release (OCABR) in accordance with Article 82 of Directive 2001/82/EC as amended.] 
<Za to zdravilo je potreben postopek uradne kontrole in sproščanja (OCABR postopek).> [only for those immunological veterinary medicinal products which are listed for Official Control Authority Batch Release (OCABR) in accordance with Article 82 of Directive 2001/82/EC as amended.]
MARKETING AUTHORISATION NUMBER(S) EU/2/00/000/000 
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/0/00/000/000
ATC vet code: {lowest available level (e.g. subgroup for chemical substance)}. 
, oOznaka ATC vet: {najnižja razpoložljiva raven (npr. podskupina za kemijsko snov)}.
<Alternatively you can report via your national reporting system {national system details}.> [For MRP/DCP only] 
<Poročate lahko tudi preko nacionalnega sistema za poročanje {podatki nacionalnega sistema}.> [For MRP/DCP only]
<None known.> <No data available.> 
<Niso znane.> <Ni podatkov.>
b) the disease to which the product is intended to confer immunity is largely absent from the territory in question.> 
b) bolezen, za katero se z zdravilom pridobi imunost, na zadevnem območju skoraj ni prisotna.
<None known.> 
<Niso znane.>
<Do not use within {X} weeks of onset the start of the laying period.> 
<Ne uporabite v obdobju {X} tednov pred začetkom obdobja nesnosti .>
<Fertility:> <Do not use in breeding animals.> 
<Plodnost:> <Ne uporabite pri vzrejnih živalih.>
<According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal products on the whole or part of its territory if it is established that: 
<Skladno z 71. členom Direktive 2001/82/ES Evropskega parlamenta in Sveta z vsemi dopolnitvami in spremembami lahko država članica, skladno z nacionalno zakonodajo, prepove izdelavoproizvajanje, uvoz/vnos, posedovanje, prodajo, oskrbo in/ali uporabo imunološkega zdravila za uporabo v veterinarski medicini na svojem celotnem ozemlju ali delu ozemlja, če ugotovi da:
<Immunocompromised persons are advised to avoid contact with the <vaccine><immunological veterinary medicinal product> and vaccinated animals during {period}.> 
<Imunokompromitiranim osebam se svetuje, da se izogibajo stiku s <cepivom> <imunološkim zdravilom> in cepljenimi živalmi {obdobje}.>
<PHARMACOLOGICAL><IMMUNOLOGICAL> PROPERTIES Pharmacotherapeutic group: {group}. 
<FARMAKOLOŠKE> <IMUNOLOŠKE> LASTNOSTI Farmakoterapevtska skupina: {skupina}.
These measures should help to protect the environment.> 
Taki ukrepi pomagajo varovati okoljeZdravilo odstranite na okolju prijazen način.>
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary 
4.10 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi), (če je potrebno) 4.11 Karenca <Ni smiselno.>
4.2 Indications for use, specifying the target species <Onset of immunity: {x weeks}> <Duration of immunity: {x years}> 
4.2 Indikacije za uporabo pri ciljnih živalskih vrstah <Nastop imunosti: {x tednov}> <Trajanje imunosti: {x let}>
<Laying birds:> <Do not use in <birds in lay><breeding birds> <and within 4 weeks before the onset start of the laying period>.> 
< Ptice v obdobju nesnosti:> <Ne uporabite <pri pticah v obdobju nesnosti> < vzrejnihe pticahe> <in/ 4 tedne pred začetkom obdobja nesnosti.>
Since this <vaccine> <immunological veterinary medicinal product> has been prepared with live, attenuated microorganisms, appropriate measures should be taken to prevent contamination of the handler and other people that collaborate in the process.> 
Ker je bilo <cepivo> <imunološko zdravilo> izdelano iz živih oslabljenih mikroorganizmov, so potrebni ustrezni ukrepi, da bi preprečili okužbo osebe, ki pride v stik s cepivom ter drugih oseb, ki sodelujejo pri cepljenju.>
<The <vaccine><immunological veterinary medicinal product> can be pathogenic for humans. 
<Cepivo> <imunološko zdravilo> je za človeka lahko patogeno.
<5.1 Pharmacodynamic properties> <5.2 Pharmacokinetic particulars> <Environmental properties> 
<5.1 Farmakodinamične lastnosti> <5.2 Farmakokinetični podatki>
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/). 
<Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency) (http://www.ema.europa.eu/.
<Not applicable.> <In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.> <Do not mix with any other veterinary medicinal product<, except <diluentsolvent or other component> <recommended><supplied> <for use with the veterinary medicinal product>.> 
<Ni smiselno.> <Zaradi pomanjkanja študij kompatibilnosti tega zdravila ne smemo mešati z drugimi zdravili za uporabo v veterinarski medicini.> <Ne mešajte z nobenim drugim zdravilom za uporabo v veterinarski medicini <, razen z vehikloms topilom ali drugo komponento> <, ki je priporočena> <, ki je priložena> < za uporabo s tem <zdravilom><cepivom>>.>
Personnel involved in attending vaccinated {species} should follow general hygiene principles (changing clothes, wearing gloves, cleaning and disinfection of boots) and take particular care in handling animal waste and bedding materials litter from recently vaccinated {species}.> 
Osebje, ki oskrbujejo cepljene {živalske vrste} morajo upoštevati splošna higienska načela (menjava obleke, uporaba rokavic, čiščenje in razkuževanje čevljev) in morajo še posebej paziti pri ravnanju s steljoz iztrebkiizločki in steljonastiljem {živalskih vrst}, ki so bile pred kratkim cepljene.> <Namenjeno uporabniku:
<This veterinary medicinal product does not require any special temperature storage conditions.>***** 
<Za shranjevanje zdravila ni posebnih temperaturnih omejitev.>*****
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon. 
Če opazite kakršne koli resne stranske učinke, tudi tiste, ki niso navedeni v tem navodilu za uporabo ali mislite, da zdravilo ni delovalo, druge učinke, ki niso omenjeni v teh navodilih za uporabo,
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
<POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO
<Not applicable.> <Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.> 
<Vsako neporabljeno zdravilo za uporabo v veterinarski medicini ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi predpisizahtevami.>
<EXP {month/year}> <Once <broached><opened><diluted><reconstituted> <use by…> <use within…> <use immediately>.> 
<EXP {mesec/leto}> < <Načeto> <odprto> <razredčeno> <rekonstituirano> zdravilo uporabite do…> <uporabite v…> <uporabite takoj>.>
Name and address of the manufacturer
 responsible for batch release {Name and address} <The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.> 
Ime in naslov izdelovalcaproizvajalca (izdelovalcevproizvajalcev) zdravila, odgovornega (odgovornih) za sproščanjestitev serije {Ime in naslov} <V natisnjenem navodilu za uporabo zdravila mora biti navedeno ime in naslov izdelovalcaproizvajalca, odgovornega za sproščanje zadevne serije.>
<Date of first authorisation:> <{DD/MM/YYYY}><{DD month YYYY}.> <Date of last renewal:> <{DD/MM/YYYY}> <{DD month YYYY}.> 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET <{DD/MM/LLLL}> <{DD mesec LLLL}>… <Datum pridobitve dovoljenja za promet: > <{DD/MM/LLLL}> <{DD mesec LLLL}.> <Datum zadnjega podaljšanja dovoljenja za promet: > <{DD/MM/LLLL}> <{DD mesec LLLL}.>
<The <veterinary medicinal product><vaccine><immunological veterinary medicinal product> should be given at different sites.> 
< To <zdravilo> <cepivo> < imunološko zdravilo> se daje na različna mesta.
<The manufacture, import, possession, sale, supply and/or use of {invented name} may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation. 
<Izdelava,uvoz/vnos, posedovanje, prodaja, oskrba in/ali uporaba zdravila {izmišljeno ime} je lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajo.
<Lactation:> <Not applicable.> 
<Laktacija:> <Ni smiselno.>
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/). 
DATUM ZADNJE ODOBRITVE NAVODIL ZA UPORABO <Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency) (http://www.ema.europa.eu/).>
<Special precautions for use in animals:> <Special precautions to be taken by the person administering the veterinary medicinal product to animals:> <Pregnancy:> <Lactation:> <Pregnancy and lactation:> <Lay:> <Fertility:> <Interaction with other medicinal products and other forms of interaction:> <Overdose (symptoms, emergency procedures, antidotes):> <Incompatibilities:> 
POSEBNO(A) OPOZORILO(A) <Jih ni.> <Posebna opozorila za vsako ciljno živalsko vrsto: > <Posebni previdnostni ukrepi za uporabo pri živalih: > <Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo: > <Brejost: > <Laktacija: > <Brejost in laktacija: > <Nesnost: > <Plodnost::> <Medsebojno delovanje z drugimi zdravili in druge oblike interakcij: > <Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi): > <Inkompatibilnosti: >
<Manufacturer responsible for batch release:> 
<ProizvajalecIzdelovalec, odgovoren za sproščanje serij:>
<The vaccine strain can be found in the environment for up to {x <days><weeks>}. 
<Vakcinalni sev je možno najti v okolju v obdobju do {x <dni> <tednov>}.
A decision to use this <vaccine><immunological veterinary medicinal product> before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.> 
Zato se za uporabo tega <cepiva> <imunološkega zdravila> pred ali po uporabi katerega koli drugega zdravila za uporabo v veterinarski medicini odločamo od primera od primera.
<OBLIGATION TO CONDUCT POST-AUTHORISATION MEASURES> <The MAH shall complete, within the stated timeframe, the following measures: Description 
ZDRAVILA> <OBVEZNOST IZVEDBE UKREPOV PO PRIDOBITVI DOVOLJENJA ZA PROMET> <Imetnik dovoljenja za promet z zdravilom mora v spodaj navedenem časovnem okviru izvesti naslednje ukrepe: Opis
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER IMETNIKA DOVOLJENJA ZA IZDELAVOPROIZVAJALEC ZDRAVILA, ODGOVORENEGA ZA SPROŠČANJE SERIJ V EGP, ČE STA RAZLIČNA
<The periodic safety update report (PSUR) cycle should be restarted for submission of 6 monthly reports (covering all authorised presentations of the product) for the next two years, followed by yearly reports for the subsequent two years and thereafter at 3 yearly intervals.The data lock point (DLP) for the next PSUR would be {add DLP}.>[Only applicable, if justified after authorisation.] 
<Posebne farmakovigilančne zahteve:> <Cikel rednih posodobljenih poročil o varnosti zdravila (PSUR) se ponovno začne z oddajo šestmesečnih poročil (vključene so vse odobrene oblike zdravila) v obdobju naslednjih dveh let, ki mu sledi oddaja dveh letnih poročil za naslednji dve leti, po tem obdobju pa se poročila oddajajo v triletnih obdobjih.
<This veterinary medicinal product does not require any special storage conditions.> <This veterinary medicinal product does not require any special temperature storage conditions.>***** 
< Za shranjevanje zdravila niso potrebna posebnaih navodila.> <Za shranjevanje zdravila ni posebnih temperaturnih omejitev.>*****
<None.> 
<Nič dni.>
<This veterinary medicinal product does not require any special storage conditions.> 
< Za shranjevanje zdravila niso potrebna posebnaih navodila.
<Not applicable.> 
<Ni smiselno.>
<Dispose of waste material in accordance with local requirements.> <Disposal: read package leaflet.> 
<Odpadne stvari snovi odstranite v skladu z lokalnimi predpisizahtevami.
The Committee for Medicinal Products for Veterinary Use has recommended the inclusion of {name of the active substance(s)} in {name of the product} in table 1 (Allowed substances) of the annex to Commission Regulation (EU) No 37/2010 as follows: 
<Odbor za zdravila za uporabo v veterinarski medicini je priporočil vključitev {< ime zdravilne učinkovine}> v {<ime zdravila}> v tabeloi 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.
<This being an approval under exceptional circumstances and pursuant to Article 39(7) of Regulation (EC) No 726/2004, the MAH shall conduct, within the stated timeframe, the following measures: 
(7) Uredbe (ES) št. 726/2004, mora imetnik dovoljenja za promet v spodaj navedenem časovnem okviru izvesti naslednje ukrepe:
Any person intending to manufacture, import, possess, sell, supply and use <invented name> must consult the relevant Member State's competent authority on the current vaccination policies prior to the manufacture, import, possession, sale, supply and/or use.> <Any person intending to manufacture, import, possess, sell, supply and use this veterinary medicinal product must first consult the relevant Member State's competent authority on the current vaccination policies, as these activities may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.> 
Vsakdo, ki namerava izdelovatiproizvajati, uvažati oziroma vnašati, posedovati, prodajati, oskrbovati in/ali uporabljati to zdravilo <izmišljeno ime>, se mora najprej posvetovati s pristojnim organom posamezne države članice o veljavnih programih cepljenja , saj so lahko te dejavnosti prepovedane v državi članici na njenem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajoše pred izdelavo, uvozom oziroma vnosom, posedovanjem, prodajo, oskrbo in/ali uporabo.>
<The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals treated ) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).> 
- zelo pogosti (neželeni učinki se pokažejo pri več kot 1 živali od 10 zdravljenih živali med enim ciklom zdravljenja) - pogosti (pri več kot 1, toda a manj kot 10 živali od 100 zdravljenih živali) - občasni (pri več kot 1, toda a manj kot 10 živali od 1.000 zdravljenih živali) - redki (pri več kot 1, toda a manj kot 10 živali od 10.000 zdravljenih živali) - zelo redki (pri manj kot 1 živali od 10.000 zdravljenih živali, vključnoujoč s posamezneimi primerie).>
<The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).> 
- zelo pogosti (neželeni učinki se pokažejo pri več kot 1 živali od 10 zdravljenih živali med enim ciklom zdravljenja) - pogosti (pri več kot 1, toda a manj kot 10 živali od 100 zdravljenih živali) - občasni (pri več kot 1, toda a manj kot 10 živali od 1.000 zdravljenih živali) - redki (pri več kot 1, todaa manj kot 10 živali od 10.000 zdravljenih živali) - zelo redki (pri manj kot 1 živali od 10.000 zdravljenih živali, vključujočno s posamezneimi primerei).>
Animal species MRLs Target tissues 
MRL Ciljna tkiva
<Not applicable.> <Zero days.> <<Meat and offal><Eggs><Milk> <Honey>: {X} <days><hours>.> <{X} degree days.> 
<<Meso in organi> <Mleko> <Jajca> <Med> : <{X} <ur> <dni>.> <{X} dnevnih stopinj}.>
<Consideration should be given to official guidance on the incorporation of medicated premixes in final feeds.> 
<Upoštevati je treba uradna priporočila o dodajanju zdravilnih predmešanicpredmešanice za pripravo zdravilne krme mešanice v krmo.>
<Safety> <and> <efficacy> data are available which demonstrate that this <vaccine><immunological veterinary medicinal product> can be administered at least {X} <days><weeks> <before><after> the administration of {description of tested product(s). 
< Podatki o varnosti <in> <učinkovitosti> so pokazali, da je to <cepivo> <imunološko zdravilo> varno dati vsaj {X} <dni> <tednov> <pred> <po> dajanju { opis testiranega(ih) proizvoda(ov)}.>